Executives at telehealth startup Cerebral told their clinicians that the company will stop prescribing Adderall and other controlled substances to treat attention deficit hyperactivity disorder, the company announced Wednesday.
Driving the news: The decision comes after Cerebral's preferred pharmacy, Truepill, said it would halt prescriptions for Adderall and other controlled substances, the Wall Street Journal reported last week.
